American Journal of Clinical Dermatology

, Volume 11, Issue 4, pp 225–232

Allopurinol in Dermatology

Review Article Allopurinol in Dermatology

DOI: 10.2165/11533190-000000000-00000

Cite this article as:
Tsai, TF. & Yeh, TY. Am J Clin Dermatol (2010) 11: 225. doi:10.2165/11533190-000000000-00000

Abstract

Off-label use is common in dermatology, and is inevitable for rare cutaneous diseases such as perforating dermatosis. Allopurinol is traditionally considered to be a drug for hyperuricemia only, but the recent demonstration of its efficacy in congestive heart failure has spurred renewed interest in its application in other clinical specialties. In dermatology, allopurinol is best known for its severe cutaneous adverse reactions. Recent genomic studies conducted in Taiwan have discovered useful HLA markers for determining the susceptibility of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with allopurinol.

Allopurinol has also been used in a number of dermatologic disorders including acquired reactive perforating collagenosis, sarcoidosis, psoriasis and granulomas caused by methacrylate microspheres, silicon and tattoos. Allopurinol may express its therapeutic effects via its antioxidation or anti-inflammatory properties, or its ability to improve vascular function.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of DermatologyNational Taiwan University HospitalTaipeiTaiwan
  2. 2.Faculty of MedicineUniversity of GlasgowGlasgowUK

Personalised recommendations